Literature DB >> 16087788

Differing administration time-dependent effects of aspirin on blood pressure in dipper and non-dipper hypertensives.

Ramón C Hermida1, Diana E Ayala, Carlos Calvo, José E López, Artemio Mojón, Marta Rodríguez, José R Fernández.   

Abstract

Aspirin is a potent antioxidative agent that reduces vascular production of superoxide, prevents angiotensin II-induced hypertension, and induces NO release. Low-dose aspirin administered at bedtime, but not on awakening, has also been shown to reduce blood pressure, possibly enhancing the nocturnal trough in NO production. Because endothelium-dependent vasodilation is blunted through a decrease in NO release in non-dipper compared with dipper patients, we compared the administration time-dependent influence of aspirin on ambulatory blood pressure in dipper and non-dipper hypertensive subjects. We studied 257 patients with mild hypertension (98 men and 159 women), 44.6+/-12.5 years of age, randomly assigned to receive 100 mg per day of aspirin either on awakening or at bedtime. Ambulatory blood pressure was measured for 48 hours at baseline and after 3 months of intervention. Blood pressure was slightly elevated after aspirin on awakening (increase of 1.5/1.0 mm Hg in the 24-hour mean of systolic/diastolic blood pressure; P<0.028). A highly significant blood pressure reduction was observed in patients who received aspirin at bedtime (decrease of 7.2/4.9 mm Hg in systolic/diastolic blood pressure; P<0.001). The reduction in nocturnal blood pressure mean was double in non-dippers (11.0/7.1 mm Hg) compared with dippers (5.5/3.3 mm Hg; P<0.001). This prospective trial corroborates the significant administration time-dependent effect of low-dose aspirin on blood pressure, mainly in non-dipper hypertensive patients. The timed administration of low-dose aspirin could thus provide a valuable approach, beyond prevention of cardiovascular disease, in the blood pressure control of patients with mild hypertension.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16087788     DOI: 10.1161/01.HYP.0000172623.36098.4e

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  20 in total

Review 1.  Antihypertensive effects of aspirin: what is the evidence?

Authors:  Leonelo E Bautista; Lina M Vera
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

2.  Medication administration discrepancies persist despite electronic ordering.

Authors:  Fern FitzHenry; Josh F Peterson; Mark Arrieta; Lemuel R Waitman; Jonathan S Schildcrout; Randolph A Miller
Journal:  J Am Med Inform Assoc       Date:  2007-08-21       Impact factor: 4.497

3.  Time-Dependent Hypotensive Effect of Aspirin in Mice.

Authors:  Lihong Chen; Guangrui Yang; Jiayang Zhang; Baoyin Ren; Soonyew Tang; Xuanwen Li; Garret A FitzGerald
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-12       Impact factor: 8.311

4.  Appropriateness of timing of drug administration in electronic prescriptions.

Authors:  Arwa Hassan; Walter E Haefeli
Journal:  Pharm World Sci       Date:  2010-01-10

5.  Aspirin in the prevention of preeclampsia: the conundrum of how, who and when.

Authors:  Renuka Shanmugalingam; Annemarie Hennessy; Angela Makris
Journal:  J Hum Hypertens       Date:  2018-09-19       Impact factor: 3.012

6.  A circadian gene expression atlas in mammals: implications for biology and medicine.

Authors:  Ray Zhang; Nicholas F Lahens; Heather I Ballance; Michael E Hughes; John B Hogenesch
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-27       Impact factor: 11.205

7.  Regulation on RhoA in vascular smooth muscle cells under inflammatory stimulation proposes a novel mechanism mediating the multiple-beneficial action of acetylsalicylic acid.

Authors:  Dong-Bo Li; Guo-Jie Yang; Hong-Wei Xu; Zhi-Xuan Fu; Shan-Wei Wang; Shen-Jiang Hu
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

Review 8.  Medicine in the Fourth Dimension.

Authors:  Christopher R Cederroth; Urs Albrecht; Joseph Bass; Steven A Brown; Jonas Dyhrfjeld-Johnsen; Frederic Gachon; Carla B Green; Michael H Hastings; Charlotte Helfrich-Förster; John B Hogenesch; Francis Lévi; Andrew Loudon; Gabriella B Lundkvist; Johanna H Meijer; Michael Rosbash; Joseph S Takahashi; Michael Young; Barbara Canlon
Journal:  Cell Metab       Date:  2019-08-06       Impact factor: 27.287

9.  Salicylates dilate blood vessels through inhibiting PYK2-mediated RhoA/Rho-kinase activation.

Authors:  Zhekang Ying; Fernanda R C Giachini; Rita C Tostes; Robert Clinton Webb
Journal:  Cardiovasc Res       Date:  2009-03-10       Impact factor: 10.787

10.  [Sequelae of hypertenson: kidney disease].

Authors:  W H Hörl
Journal:  Internist (Berl)       Date:  2006-03       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.